Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Update

Vigil Neuroscience, Inc. (NASDAQ:VIGL) saw a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 1,810,000 shares, a growth of 145.8% from the January 15th total of 736,500 shares. Based on an average daily volume of 1,010,000 shares, the days-to-cover ratio is presently 1.8 days. Currently, 9.4% of the company’s shares are short sold.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on VIGL. JMP Securities reissued a “market outperform” rating and issued a $22.00 price objective on shares of Vigil Neuroscience in a research note on Tuesday, November 26th. HC Wainwright reaffirmed a “buy” rating and set a $17.00 price target on shares of Vigil Neuroscience in a research note on Thursday, January 23rd. Guggenheim reaffirmed a “buy” rating on shares of Vigil Neuroscience in a research note on Friday, January 24th. Wedbush upped their price target on Vigil Neuroscience from $23.00 to $24.00 and gave the stock an “outperform” rating in a research note on Friday, November 8th. Finally, William Blair assumed coverage on Vigil Neuroscience in a research note on Wednesday, December 4th. They set an “outperform” rating on the stock. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $19.75.

Institutional Investors Weigh In On Vigil Neuroscience

Large investors have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. grew its stake in shares of Vigil Neuroscience by 7.7% during the third quarter. Point72 Asset Management L.P. now owns 1,600,000 shares of the company’s stock valued at $5,440,000 after buying an additional 115,000 shares during the last quarter. abrdn plc grew its stake in shares of Vigil Neuroscience by 124.9% during the fourth quarter. abrdn plc now owns 528,472 shares of the company’s stock valued at $898,000 after buying an additional 293,461 shares during the last quarter. Blair William & Co. IL bought a new position in shares of Vigil Neuroscience during the fourth quarter valued at about $551,000. Geode Capital Management LLC grew its stake in shares of Vigil Neuroscience by 41.9% during the third quarter. Geode Capital Management LLC now owns 226,083 shares of the company’s stock valued at $769,000 after buying an additional 66,712 shares during the last quarter. Finally, Verition Fund Management LLC bought a new position in shares of Vigil Neuroscience during the third quarter valued at about $442,000. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Vigil Neuroscience Price Performance

NASDAQ VIGL traded up $0.02 during trading hours on Wednesday, reaching $2.67. 961,942 shares of the stock traded hands, compared to its average volume of 1,990,923. The stock has a 50 day simple moving average of $2.03 and a two-hundred day simple moving average of $2.95. Vigil Neuroscience has a 1 year low of $1.49 and a 1 year high of $6.06. The company has a market cap of $108.95 million, a price-to-earnings ratio of -1.29 and a beta of 1.84.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.